Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 2, 2021, the compensation committee (the "Compensation Committee")
of the Board of Directors of VYNE Therapeutics Inc. (the "Company") approved the
grant of an aggregate of 1,204,909 shares subject to restricted stock unit and
stock option awards to all continuing employees of the Company, including
members of management. The awards will be issued in accordance with the terms
and conditions of the Company's 2019 Equity Incentive Plan and the 2018 Omnibus
Incentive Plan and the underlying award agreements. The Compensation Committee
determined such grants are appropriate to address the need to adequately retain
the Company's employees through this period of strategic change and incentivize
employees to effectively execute the Company's new strategic operating plan, as
disclosed on August 12, 2021, and closely align the interests of employees with
the Company's stockholders over the long term.
David Domzalski, the Company's Chief Executive Officer, was awarded 320,312
restricted stock unit awards and employee stock options to purchase 320,313
shares. Iain Stuart, the Company's Chief Scientific Officer, Tyler Zeronda, the
Company's Chief Financial Officer, and Mutya Harsch, the Company's Chief Legal
Officer, were each awarded 60,859 restricted stock unit awards and employee
stock options to purchase 60,860 shares. All of the shares subject to restricted
stock unit awards will vest on September 30, 2023, and 50% of the shares subject
to stock option awards will vest on September 30, 2022, with the remaining 50%
of the shares vesting thereafter in equal, quarterly installments, in each case,
subject to the recipient's continued service to the Company through the vesting
date. The exercise price for each stock option granted is $1.68 per share, which
represents the closing price for the Company's common stock on the date of
grant.
© Edgar Online, source Glimpses
VYNE THERAPEUTICS INC. 
